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Sildenafil, an inhibitor of the cGMP-degrading
phosphodiesterase 5 that is used to treat erectile
dysfunction, has been linked to an increased risk of
melanoma. Here, we have examined the potential
connection between cGMP-dependent signaling
cascades and melanoma growth. Using a combina-
tion of biochemical assays and real-time monitoring
of melanoma cells, we report a cGMP-dependent
growth-promoting pathway in murine and human
melanomacells.Wedocument that C-type natriuretic
peptide (CNP), a ligand of themembrane-bound gua-
nylate cyclase B, enhances the activity of cGMP-
dependent protein kinase I (cGKI) in melanoma cells
by increasing the intracellular levels of cGMP. Activa-
tion of this cGMP pathway promotes melanoma cell
growth and migration in a p44/42 MAPK-dependent
manner. Sildenafil treatment further increases intra-
cellular cGMP concentrations, potentiating activa-
tion of this pathway. Collectively, our data identify
this cGMP-cGKI pathway as the link between silden-
afil usage and increased melanoma risk.
INTRODUCTION
Malignant melanoma is one of the most aggressive cancers. It
arises frommelanocytes and accounts for the majority of deaths
related to skin cancer. In theWestern world, its incidence almost
doubles each decade. If melanoma is diagnosed early, it can be
curedby surgical resection. However, due to its distinct tendency
tometastasize, in about 20%of patients it progresses to an inva-
sivedisease that is refractory to therapyandhasapoor prognosis
(Gray-Schopfer et al., 2007;Miller andMihm, 2006). At themolec-
ular level, the mitogen-activated protein kinase (MAPK) pathway
is hyperactivated in the majority of melanomas, and this typically
occurs through somatic gain-of-function mutations in either
NRAS (15%–20% cutaneous melanomas) or BRAF (40%–Cell50%). These mutations can be identified in benign melanocytic
proliferation and all stages of invasive and metastatic melanoma
(Lo and Fisher, 2014; Omholt et al., 2003; Shtivelman et al., 2014;
Sullivan and Flaherty, 2013). Interestingly, oncogenic BRAF
signaling and invasiveness of melanoma cells in mice are associ-
ated with an increased level of cyclic guanosine-30, 50-mono-
phosphate (cGMP) due to downregulation of PDE5A gene
expression, which encodes the cGMP-degrading phosphodies-
terase 5 (PDE5) (Arozarena et al., 2011). In this study, melanoma
cell invasion could be induced in vitro by the PDE5 inhibitor sil-
denafil, which is clinically used to treat erectile dysfunction and
pulmonary hypertension. Moreover, a recent prospective cohort
study inmen in theUnitedStates indicated that sildenafil usemay
be linked to an increased risk of developing melanoma (Li et al.,
2014). Together, these findings point to a crosstalk between
cGMP and MAPK signaling that might be relevant to the patho-
physiology and therapy ofmelanoma inmouse and human. How-
ever, the molecular players of cGMP signaling, for example, the
cGMP generators and effectors, in melanoma cells are not well
characterized.
cGMP is an intracellular signaling molecule that transmits the
effects of NO and various peptides and regulates diverse cellular
functions in eukaryotes (Beavo and Brunton, 2002; Kemp-
Harper and Feil, 2008; Kots et al., 2009). It can be generated
from GTP by two classes of guanylate cyclases, NO-sensitive
soluble guanylate cyclases (sGCs) (Mergia et al., 2009) or pep-
tide-activated membrane-bound guanylate cyclases (Kuhn,
2009; Potter et al., 2006), such as the atrial natriuretic peptide
(ANP)-responsive GC-A or the C-type natriuretic peptide
(CNP)-responsive GC-B. The amplitude and duration of cGMP
signals are regulated through a dynamic balance between its
rate of synthesis by guanylate cyclases and degradation by
phosphodiesterases (Francis et al., 2009). In many cell types,
themajor downstream effector of cGMP is the cGMP-dependent
protein kinase I (cGKI, also known as protein kinase G or PKG),
which belongs to the serine/threonine family of protein kinases
(Hofmann et al., 2006). The mammalian prkg1 gene encodes
two isoforms of cGKI, cGKIa and cGKIb, which differ in their
N-terminal region of approximately 100 amino acids. cGKI activ-
ity in intact cells can be monitored by immunodetection ofReports 14, 2599–2610, March 22, 2016 ª2016 The Authors 2599
Figure 1. B16 Melanoma Cells Express
Functional cGKI
(A) Expression of cGKIa and cGKIb mRNA in B16
melanoma cells as detected by RT-PCR. RNA
from mouse lung and aorta served as positive
controls and water as negative a control. GAPDH
was used as a loading control. A DNA size marker
was loaded in the left lane.
(B) Detection of cGKIa and cGKIb protein in
B16 melanoma cell lysates (10 mg) by western
blot with antibodies that recognize both cGKI
isoforms (cGKI) or selectively cGKIa or cGKIb.
Purified cGKI isozymes (5 ng) served as
controls.
(C) Immunofluorescence staining of B16F10 cells
with the cGKI antibody (green); nuclei (blue); scale
bar, 25 mm.
(D) B16F10 cells were incubated for 10 min in PBS
(‘‘0’’) or with the indicated concentrations of
8-Br-cGMP. Then, protein lysates (10 mg) were
analyzed by western blot with antibodies detect-
ing phospho-PDE5 (p-PDE5), cGKI, or phospho-
VASP (p-VASP) and VASP.
(E) B16F10 cells were incubated for 10 min under
control conditions (PBS) or in the presence of
100 mM 8-Br-cAMP or 100 mM 8-Br-cGMP. Then, protein lysates (10 mg) were analyzed by western blot with antibodies against cGKI or p-VASP/VASP.
For thewestern blots shown in (B), (D), and (E), GAPDHwas used as a loading control. Representative data from one of three independent experiments are shown.phosphorylated cGKI substrate proteins such as vasodilator-
stimulated phosphoprotein (VASP) (Lohmann and Walter, 2005)
or PDE5 (Rybalkin et al., 2002).
It is well established that activation of the cGMP-cGKI axis ex-
erts acute cardiovascular effects such as relaxation of vascular
smooth muscle and modulation of platelet aggregation. Addi-
tionally, cGMP has been implicated in the regulation of growth
and survival in multiple cell types including tumor cells (Fajardo
et al., 2014; Feil et al., 2003, 2005). The role of cGMP in cancer
appears to be complex and dependent upon the type of tumor
and model system under investigation (Barsoum et al., 2014; Fa-
jardo et al., 2014; Ying and Hofseth, 2007; Zhang et al., 2014).
Both pro- and anti-cancer effects of cGMP have been reported.
The variable effects of cGMP on tumor growth are likely due to
the fact that different tumor cells express different cGMP gener-
ators and effectors and that cGMP signaling also affects various
processes in the tumor microenvironment, such as blood flow,
angiogenesis, inflammation, and immune response.
The aim of the present study was to characterize the expres-
sion and functional role of components of the cGMP signaling
system in melanoma cells of murine and human origin. We
have identified a cGMP pathway that promotes MAPK signaling
and melanoma growth in vitro and in vivo. Importantly, it was
found that the growth-promoting cGMP pathway could be
potentiated pharmacologically by treatment of melanoma cells
or mice with sildenafil.
RESULTS
Identification of a CNP-cGMP-cGKI Pathway in B16
Melanoma Cells
Initially, we analyzed the expression and function of cGMP
signaling pathway components in murine B16 melanoma cells.2600 Cell Reports 14, 2599–2610, March 22, 2016 ª2016 The AuthorAt the mRNA level, we detected the expression of the cGKIa
isoform, but not the cGKIb isoform, in B16F1 as well as
B16F10 cells (Figure 1A). The selective expression of the cGKIa
isozyme was confirmed at the protein level by western blot anal-
ysis with isoform-specific antibodies (Figure 1B) and immuno-
fluorescence staining of cells (Figure 1C). Unless otherwise
stated, subsequent experiments were performed with B16F10
cells. To monitor cGKI enzymatic activity in intact cells, we
analyzed phosphorylation of the cGKI substrates, PDE5 and
VASP. Phospho-PDE5 was detected with a phospho-specific
antiserum and phospho-VASP was detected with an antiserum
that recognizes both dephospho-VASP and phospho-VASP
(phosphorylated at Ser157). Phospho-VASP (Ser157) migrates
at a discernible higher molecular weight compared to dephos-
pho-VASP. VASP can be phosphorylated on Ser 157 by multiple
kinases including cGKIa, cGKIb, and cAMP-dependent protein
kinase (cAK) (Lohmann and Walter, 2005; Weber et al., 2007).
B16 cells expressed both PDE5 and VASP, and treatment of
intact cells with the membrane-permeable cGMP analog and
cGKI activator, 8-Br-cGMP, stimulated the phosphorylation of
both PDE5 and VASP in a dose-dependent manner (Figure 1D).
To test for the presence of a functional cAMP-cAK pathway,
B16 cells were incubated with the cAK activator, 8-Br-cAMP,
and then phosphorylation of VASP was monitored. However,
the level of phospho-VASP induced by 8-Br-cAMP (100 mM)
was much smaller than with an equimolar concentration of
8-Br-cGMP (Figure 1E). Taken together, these findings showed
that B16 melanoma cells express functional cGKI as well as
its substrates VASP and PDE5, and that the cGMP-cGKI
pathway might be more prominent than the cAMP-cAK pathway
in these cells. While PDE5 could be involved in cGMP-degrada-
tion in B16 cells, it was not clear how cGMP is generated in
these cells.s
Figure 2. B16 Melanoma Cells Express a CNP-cGMP-cGKI Pathway
(A) Expression of mRNA encoding the membrane-bound guanylate cyclases,
GC-A andGC-B, or the soluble guanylate cyclase subunits, sGCa1 and sGCb1,
in B16 melanoma cells as detected by RT-PCR. RNA from mouse lung and
aorta served as positive controls and water as a negative control. GAPDH was
used as a loading control. A DNA size marker was loaded in the left lane.
(B) Cyclic nucleotide levels in B16F10 cells. Cells were incubated for 10 min
under control conditions (PBS) or with 1 mM ANP, 1 mM CNP, or 100 mM DEA/
NO. Then, cells were lysed and cGMP (black bars) or cAMP (gray bars) levels
were determined in cell extracts by enzyme immunoassays. Data are pre-
sented as mean ± SEM (n = 3); ***p < 0.001 compared to PBS. Representative
data from one of two independent experiments are shown.
(C) Real-time imaging of cGMP signals in living B16F10 cells by FRET micro-
scopy. Cells were transfected with the fluorescent FRET-based cGMP sensor,
cGi500. To trigger cGMP elevations, cells were superfused with increasing
concentrations of CNP (horizontal bars). CFP and YFP emissions were
simultaneously recorded (light gray and gray traces, respectively). The CFP/
YFP ratio (black trace) reflects the intracellular cGMP concentration. The di-
agram shows the response of an individual B16 cell that was representative of
ten cells measured overall.
(D) B16F10 cells were incubated for 10min under control conditions (PBS) or in
the presence of 100 mM 8-Br-cGMP (cG) or 1 mM CNP. Then, protein lysates
(10 mg) were analyzed by western blot with the indicated antibodies. GAPDH
was used as a loading control. Representative data from one of three inde-
pendent experiments are shown.
See also Figure S1.To identify the cGMP-generating mechanism(s) in B16 cells,
the mRNA expression of guanylate cyclases was analyzed in
B16F1 and B16F10 cells. We detected very weak expression
of the ANP receptor, GC-A, relatively strong expression of the
CNP receptor, GC-B, and no expression of the a1 and b1 sub-
units of the NO receptor, sGC (Figure 2A). To test the ability of
the melanoma cells to generate endogenous cGMP, intact cells
were incubated with physiological stimulators of the respective
guanylate cyclases, and then cGMP was measured in cell ex-
tracts by enzyme immunoassay. In line with their expression pro-Cellfile for guanylate cyclases, treatment of B16 cells with ANP
(1 mM), CNP (1 mM), or the NO-releasing compound DEA/NO
(100 mM) resulted in a weak increase, strong increase, or no sig-
nificant change of the intracellular cGMP concentration, respec-
tively, as compared to control conditions (PBS) (Figure 2B, black
bars). None of the compounds significantly altered the level of
cAMP in B16 cells compared to control conditions (PBS) (Fig-
ure 2B, gray bars). The dynamic change of cGMP signals upon
CNP stimulation could also be visualized in real time in livingmel-
anoma cells that expressed a cGMP biosensor. B16 cells were
transfectedwith an expression plasmid encoding the fluorescent
cGMP sensor, cGi500 (Russwurm et al., 2007; Thunemann et al.,
2013b). This sensor contains the cGMP-binding domain of the
cGKI flanked by CFP and YFP. Binding of cGMP alters the sen-
sor’s conformation and the efficiency of fluorescence resonance
energy transfer (FRET) from CFP to YFP. Thus, the FRET-based
cGi500 sensor reports changes of the cGMP concentration
via a change in its CFP/YFP emission ratio. Application of CNP
increased the intracellular cGMP concentration dose-depen-
dently as indicated by the CFP/YFP ratio (Figure 2C, black trace).
Moreover, the physiological GC-B ligand, CNP (1 mM), was as
effective as the synthetic cGMP analog, 8-Br-cGMP (100 mM),
in stimulating phosphorylation of the cGKI substrates, PDE5
and VASP, in intact B16 cells (Figure 2D). Thus, we concluded
that B16 melanoma cells express a functional CNP-cGMP-
cGKI pathway.
cGMP Promotes B16 Melanoma Cell MAPK Signaling,
Growth, and Migration
To determine the downstream mechanisms and functions of
cGMP in melanoma cells, we tested the effects of pharmacolog-
ical and physiological stimulation of cGMP signaling with 8-Br-
cGMP and CNP, respectively, on MAPK pathway activity and
on B16 cell growth and migration. Exposure of B16F10 mela-
noma cells for 10 min to 8-Br-cGMP (100 mM) or CNP (1 mM)
caused phosphorylation of PDE5 and VASP and a dramatic
increase in the phosphorylation of p44/42 MAPK (Figure 3A).
Similar results were obtained with B16F1 melanoma cells (Fig-
ure S1A). The p44/42 MAPK is normally activated by phosphor-
ylation via mitogen and extracellular signal-regulated protein
kinase kinase (MEK). Co-incubation of the cells with the MEK in-
hibitor, U0126 (10 mM), abolished CNP/cGMP-stimulated phos-
phorylation of p44/42 MAPK (Figure 3A). The cGMP-induced
MAPK phosphorylation was also suppressed by lower concen-
trations of U0126 (1 mM, 0.1 mM) as well as by two alternative
MEK inhibitors, PD98059 (50 mM, 10 mM) and trametinib (1 mM,
0.1 mM) (Figure S1B). These results indicated that cGMP acts up-
stream of MEK to promote p44/42 MAPK signaling. Incubation
with 8-Br-cGMP for 10 min and MEK inhibition did not affect
the expression level of PDE5 (Figure S1B), and MEK inhibition
did not alter the CNP/cGMP-induced phosphorylation of PDE5
(Figure 3A) and VASP (Figure 3A; Figure S1B). Thus, MAPKs
did not appear to regulate the activity of cGMP generators and
effectors under the conditions tested.
In line with their stimulating effects on MAPK activity, both
8-Br-cGMP (1 mM) and CNP (1 mM) provoked increases in mel-
anoma cell growth as measured by a conventional endpoint
assay (Figure 3B) as well as by monitoring living cells with anReports 14, 2599–2610, March 22, 2016 ª2016 The Authors 2601
Figure 3. Activation of the cGMP Pathway
in B16F10 Melanoma Cells Promotes
MAPK Signaling andMelanoma Cell Growth
In Vitro
(A) B16 cells were incubated for 10 min in PBS
(control) or in PBS in the presence of 100 mM 8-Br-
cGMP (cG), 1 mM CNP, 10 mM U0126, or 8-Br-
cGMP plus U0126, or CNP plus U0126. Protein
lysates (10 mg) were analyzed by western blot with
the indicated antibodies. GAPDH was used as a
loading control.
(B) B16 cells were grown for 48 hr under control
conditions or in the presence of 1 mM 8-Br-cGMP
(cG), 1 mMCNP, 10 mMU0126, or 8-Br-cGMP plus
U0126, or CNP plus U0126. Then, cell growth was
determinedby theMTSassay.Data are normalized
to growth under control conditions, which was
set to 1, and presented asmean ±SEM (n = 4); *p <
0.05 and **p < 0.01 compared to control.
(C and D) B16 cell growth was continuously
monitored by impedance-based RTCA. Cells
were grown under control conditions and (C) in the
presence of 1 mM 8-Br-cGMP, 10 mM U0126, or
8-Br-cGMP plus U0126, or they were grown (D) in
the presence of 1 mM CNP, 10 mM U0126, or CNP
plus U0126. Data shown are mean ± SEM (n = 3);
**p < 0.01 and ***p < 0.001 compared to control.
In (A)–(D), representative data from one of three
independent experiments are shown. See also
Figure S1.impedance-based real-time cell analyzer (RTCA) (Figures 3C and
3D). U0126 (10 mM) reduced basal and CNP/cGMP-stimulated
growth of B16 cells (Figures 3B–3D). Next, the effect of cGMP
on B16 cell migratory potential was tested in two assays. In the
scratch assay, 8-Br-cGMP (1 mM) increased the number of cells
in the wounded region after 24 hr compared to control (Figures
4A and 4B). In an alternative migration assay performed with
the RTCA, the migration of B16 cells through a membrane
(8-mm pore size) was significantly enhanced by 8-Br-cGMP
(1 mM) at 6 hr, 12 hr, and 18 hr in comparison to control
conditions (Figure 4C). Together, these findings indicated that
activation of the cGMP pathway is associated with increased
B16 melanoma cell growth and migration, presumably via a
crosstalk with MAPK signaling.
cGKI Overexpression or Sildenafil Treatment Enhances
B16 Melanoma Growth in Mice
To determine the consequences of increased cGMP signaling for
tumor growth under in vivo conditions, we analyzed the effects of
overexpressing cGKIa or sildenafil administration on B16 mela-
noma growth in mice. B16 cells infected with an adenovirus en-
coding cGKIa (Ad-cGKIa) expressed much higher amounts of
the protein kinase than cells infected with a control virus (Ad-
EGFP) (Figures 5A and 5B). Both the basal level of VASP phos-
phorylation in the presence of PBS as well as VASP phosphory-
lation induced by 8-Br-cGMP (10 mM) or CNP (5 nM) were higher
in Ad-cGKIa-infected cells than in Ad-EGFP-infected control
cells (Figure 5B). Mice that received intracutaneous injections
of cGKIa-overexpressing B16 melanoma cells developed signif-
icantly bigger tumors than mice injected with Ad-EGFP-infected2602 Cell Reports 14, 2599–2610, March 22, 2016 ª2016 The Authorcontrol cells. Fourteen days after implantation, tumors derived
from cGKIa-overexpressing B16 cells were2-fold bigger in vol-
ume and area than control tumors (Figures 5C and 5D).
Since B16 cells express PDE5 (Figures 1D, 2D, and 3A), we
askedwhether the clinically usedPDE5 inhibitor, sildenafil, would
enhance the level of cGMP and the associated downstream
signaling events in these cells. Indeed, cGMP imaging in living
B16melanomacells expressing the cGMPbiosensor, cGi500, re-
vealed that sildenafil (100 mM) strongly increased CNP-triggered
cGMP signals as compared to stimulations with CNP alone (Fig-
ure6A).Moreover, sildenafil potentiatedCNP-inducedphosphor-
ylation of PDE5, VASP, and p44/42MAPK (Figure 6B). In line with
these biochemical data, sildenafil (100 mM) enhanced CNP-stim-
ulated growth of the melanoma cells as determined by both an
endpoint assay (Figure 6C) as well as by impedance-based
real-time monitoring of cells (Figure 6D). To determine whether
PDE5 inhibition affects melanoma cell growth in vivo, B16 cells
were injected intracutaneously into mice that received sildenafil
(200 mg kg–1day–1) in their drinking water or water without the
drug. Compared to control animals, sildenafil-treated mice
showed increased cardiac cGMP levels (Figure 6E) and tumor
growth (Figure 6F). Collectively, these data showed that stimula-
tion of cGMPsignaling in B16 cells by overexpression of cGKIa or
pharmacologically via treatment with sildenafil promotes mela-
noma growth both in vitro and in vivo in mice.
TheGrowth-Promoting cGMPPathway IsAlsoPresent in
Human Melanoma Cells
Since our previous studies were performed with a mouse model,
it was important to evaluate the relevance of cGMP signaling ins
Figure 4. Activation of the cGMP Pathway Promotes B16F10 Mela-
noma Cell Migration In Vitro
(A and B) Analysis of B16 cell migration by a scratch assay. A confluent
monolayer of cells was wounded (0 hr) and then incubated for 24 hr under
control conditions or in the presence of 1 mM 8-Br-cGMP. (A) shows repre-
sentative photomicrographs of the cell monolayer (scale bars, 25 mm), and (B)
shows the quantitative evaluation of cell migration reflected by percentage of
cell-covered area. Data are presented as mean ± SEM (n = 3); ***p < 0.001
compared to untreated control at 24 hr.
(C) B16 cells were plated on membranes (8-mm pore size) and migration under
control conditions or in the presence of 1 mM 8-Br-cGMP was monitored 3, 6,
12, and 18 hr later by impedance-based RTCA. Data are presented relative to
control migration at 3 hr, which has been normalized to 1 and expressed as
mean ± SEM (n = 3); *p < 0.05, **p < 0.01 compared to the untreated control at
the respective time point.human melanoma. Indeed, expression of cGKIa and cGKIb
mRNA could be detected by qRT-PCR in several human pri-
mary/non-metastatic and metastatic melanoma cell lines (Fig-
ure 7A). Western blot analysis (Figure S2A) confirmed the
expression of cGKI in primary cell lines (WM35, WM3211) as
well as in metastatic cell lines (1205Lu, WM852, and SKMel147).
PDE5 protein was also detected in these cell lines except in
WM852 cells. The cell lines 1205Lu, WM852, and SKMel147 re-
sponded to treatment with both 8-Br-cGMP (100 mM) and CNP
(1 mM) with strongly increased phosphorylation of the cGKI sub-
strate VASP (Figure S2A). Interestingly, WM35 and WM3211
cells showed relatively weak to undetectable VASP phosphory-
lation in response to 8-Br-cGMP or CNP (Figure S2A). This could
be due to differences in the components of cGMP signaling in
these cells as compared to the other cGKI/PDE5-positive cell
lines. RT-PCR analysis of PDE expression in these human cell
lines correlated well with the western blot results for PDE5.
Furthermore, the data indicated that human melanoma cells ex-
press varying levels of other cGMP-PDEs including PDE1C,
PDE3B, PDE9A, PDE10A, and PDE11A (Figure S2B). Thus, we
cannot exclude that in addition to PDE5 other PDEs might
be involved in cGMP signaling in human melanoma cells. The
cGKI protein was also detected in melanomas from human
patients. Immunohistochemical staining of cGKI was positive inCelltumor cells of primary melanomas from nine of the 17 patients
(Figure 7B, left; data not shown) and in tumor cells of metastases
from one of the 11 patients analyzed (data not shown). Interest-
ingly, cGKI protein was not detectable in tumor cells of most me-
tastases tested, including a matched metastasis derived from a
patient with a cGKI-positive primary tumor (Figure 7B, right).
Together, the results obtained with human melanoma cell lines
and tumor tissues indicated that the cGMP-cGKI pathway is ex-
pressed in many but not all human melanomas. Importantly,
analysis of 418 melanoma patients from The Cancer Genome
Atlas (TCGA) (Weinstein et al., 2013; Cheng et al., 2015) revealed
that the median survival time of patients with high cGKI expres-
sion in their tumors is dramatically reduced compared to patients
with low cGKI expression (Figure S3).
For further functional studies, we selected the non-metastatic
human melanoma cell line WM3211 (BRAF-wild-type), and the
metastatic cell line 1205Lu (BRAF-mutated). Both cell lines ex-
pressed cGKI and PDE5 (Figure 7A; Figure S2). Both WM3211
and 1205Lu cells showed a strong increase in their intracellular
cGMPconcentration upon treatment with CNP (1 mM) and this in-
crease was further augmented by co-treatment with sildenafil
(100 mM) as measured in cell extracts by a cGMP immunoassay
(Figure 7C). Dynamic cGMPmeasurements in living 1205Lu cells
confirmed these results and showed that in addition to sildenafil,
cGMP signals were also enhanced by two other clinically used
PDE5 inhibitors, tadalafil and vardenafil (Figure S4).
Next, we asked whether stimulation of the cGMP pathway in
human melanoma cells would also promote MAPK signaling as
in murine melanoma cells. Note that, as expected, BRAF-
mutated 1205Lu cells exhibited a higher basal level of p44/42
MAPKphosphorylation than BRAF-wild-typeWM3211 cells (Fig-
ure 7D, PBS). Compared to control (PBS), 8-Br-cGMP (100 mM)
or CNP (1 mM) strongly stimulated phosphorylation of p44/42
MAPK in WM3211 cells and, to a lesser extent, also in 1205Lu
cells (Figure 7D). The latter finding was of particular interest
because it suggested that cGMPmight even be able to stimulate
the growth of BRAF-mutated melanoma cells, such as 1205Lu
cells, which already exhibit hyperactive MAPK signaling. Indeed,
8-Br-cGMP (100 mM) or CNP (1 mM) significantly increased the
growth of both WM3211 and 1205Lu cells, and sildenafil
(100 mM) further augmented the pro-growth effect of CNP in
both melanoma cell lines (Figure 7E). We conclude that, similar
to murine melanoma cells, human melanoma cells can express
a growth-promoting cGMP pathway that is also responsive to
pharmacological stimulation with sildenafil.
DISCUSSION
Previous work has indicated a role of cGMP signaling in mela-
noma, but the underlying mechanism(s) remained largely un-
known (Arozarena et al., 2011; Li et al., 2014). In the present
study, we have identified a cGMP pathway in murine and human
melanoma cells that promotes p44/42 MAPK signaling and mel-
anoma growth in vitro and in vivo. Moreover, the clinically used
PDE5 inhibitor, sildenafil, potentiated the biochemical activity
of the cGMP signaling cascade in melanoma cells and enhanced
tumor growth. With the discovery of a CNP-cGMP-cGKI-MAPK
pathway in melanoma cells, our study provides the cGMPReports 14, 2599–2610, March 22, 2016 ª2016 The Authors 2603
Figure 5. Overexpression of cGKIa Aug-
ments cGMPSignaling in B16F10Melanoma
Cells In Vitro and Tumor Growth In Vivo
(A) B16 cells were infected with a control adeno-
virus expressing EGFP (Ad-EGFP) or with an
adenovirus encoding EGFP and cGKIa (Ad-cGKIa)
and analyzed 48 hr post-infection; scale bars,
50 mm.
(B) Melanoma cells infected with Ad-EGFP or Ad-
cGKIa were incubated for 10 min in PBS or in PBS
in the presence of 10 mM 8-Br-cGMP (cG) or 5 nM
CNP. Protein lysates (10 mg) were analyzed by
western blot with the indicated antibodies.
GAPDH was used as a loading control. Values
below the panels represent fold increase in VASP
phosphorylation as determined by densitometric
analysis of the p-VASP to VASP ratio and
normalization to control conditions (Ad-EGFP-in-
fected cells incubated with PBS). Representative
data from one of two independent experiments are
shown.
(C and D) B16 melanoma cells infected with Ad-
EGFP or Ad-cGKIawere injected intracutaneously
(i.c.) into C57BL/6 mice (2 3 75,000 cells/mouse,
n = 18 injections with Ad-EGFP cells and n = 16 injections with Ad-cGKIa cells). (C) Tumor growth curves were determined by measuring the tumor volume over
time. Data are presented as mean ± SEM. Differences between groups were assessed by repeated-measures ANOVA followed by a Bonferroni t test; **p < 0.01.
(D) Mice were sacrificed on day 14, and tumor area was determined. Data are presented as mean ± SEM; ***p < 0.001 compared to tumors from Ad-EGFP-
infected cells.generator and effector mechanisms that are potentially involved
in the pro-melanoma effects of sildenafil in men.
This report describes a role for CNP and its receptor GC-B in
melanoma. We are aware of few studies that have linked CNP
signaling to tumorigenesis. One study (Lelie`vre et al., 2001)
showed that subnanomolar concentrations of CNP stimulated
the proliferation of human and rodent neuroblastoma cell lines,
presumably via activation of cGMP-dependent protein kinase.
In another study (Scho¨nrath et al., 2011), the authors observed
increased cGMP levels in murine skin squamous cell carcinoma
cells following CNP stimulation, but the functional relevance of
CNP-induced cGMP in tumor cell growth was not investigated.
Interestingly, however, the high cGMP levels in response to
CNP appeared to correlate with the aggressiveness/invasive-
ness of the analyzed tumor cell lines (Scho¨nrath et al., 2011). In
contrast to CNP, ANP and its receptor GC-A (Zhang et al.,
2014) as well as NO-derived cGMP (Barsoum et al., 2014; Ying
and Hofseth, 2007) have been previously implicated in various
cancers including melanoma. For instance, genetic GC-A defi-
ciency protected mice from grafted lung, skin, and ovarian can-
cer, possibly because GC-A positive cells in the tumor stroma
are involved in the regulation of local inflammation and tumor
angiogenesis (Kong et al., 2008). More recently, Nojiri et al.
(2015) reported that ANP via GC-A on vascular endothelial cells
prevented metastasis of B16 melanoma cells to the lung by in-
hibiting their adhesion to the inflamed endothelium. The roles
and mechanisms of cGMP signaling in melanoma cells them-
selves are, however, not well understood.
We have identified the cGMP effector cGKI as downstream
component of CNP/GC-B signaling in melanoma cells and, as
expected from previous reports, its substrates VASP (Kim
et al., 2011) and PDE5 (Arozarena et al., 2011; Drees et al.,2604 Cell Reports 14, 2599–2610, March 22, 2016 ª2016 The Author1993). While the functional significance of VASP in melanoma
cells is not clear (Kim et al., 2011), our pharmacological experi-
ments with PDE5 inhibitors (sildenafil, tadalafil, and vardenafil)
demonstrated that PDE5 contributes to the degradation of
cGMP and is, thus, an important ‘‘brake’’ for cGMP signaling in
melanoma cells. Stimulation of melanoma cells with the physio-
logical agonist CNP resulted in increased growth as determined
by conventional endpoint assays as well as by impedance-
based real-time monitoring of living cells. Mechanistically,
activation of the cGMP-cGKI cascade was associated with
increased MAPK signaling as shown by detection of phospho-
p44/42 MAPK. Experiments with MEK inhibitors (U0126,
PD98059, and trametinib) demonstrated that the cGMP pathway
interacts with MAPK signaling upstream of MEK and that this
crosstalk is required for the growth-promoting effect of cGMP
in melanoma cells.
To evaluate the potential clinical relevance of the cGMP-cGKI
pathway inmelanoma, we have analyzed humanmelanoma cells
and the effect of the PDE5 inhibitor sildenafil on melanoma
growth. Indeed, we could demonstrate the growth-promoting
cGMP cascade not only in murine B16 cells but also in human
melanoma cells, although this pathway is probably not univer-
sally conserved in all human melanomas. Importantly, treatment
with sildenafil increased the biochemical activity of the cGMP-
cGKI pathway as well as melanoma cell growth in vitro, and it
significantly enhanced melanoma growth in mice in vivo. Our re-
sults with sildenafil are in agreement with a recent study that indi-
cated a link between PDE5 and cGMP signaling in melanoma.
Arozarena et al. (2011) reported that in melanoma cells onco-
genic BRAF, acting through MEK and the transcription factor
BRN2, downregulates PDE5 expression. PDE5 downregulation
was associated with a relatively modest increase in cGMP ands
Figure 6. Sildenafil Augments cGMP Signaling in B16F10 Melanoma Cells In Vitro and Tumor Growth In Vivo
(A) Real-time imaging of cGMP signals in living B16 cells by FRET microscopy. Cells were transfected with the fluorescent FRET-based cGMP sensor, cGi500.
Elevations of cGMPwere triggered by superfusion of the cells with 100 nMCNP (short horizontal bars) in the absence and presence of 100 mMsildenafil (SIL, long
horizontal bar). The black trace denotes the CFP/YFP ratio signal, which reports the intracellular cGMP concentration. The diagram shows the response of an
individual B16 cell that was representative of ten cells measured overall.
(B) B16 cells were incubated for 10min in PBS or in PBSwith CNP (1 nM, 10 nM) in the absence (–) or presence (+) of 100 mMsildenafil (SIL). Protein lysates (10 mg)
were analyzed by western blot with the indicated antibodies. GAPDH was used as a loading control. Values below the panels represent fold increase in
phosphorylation of PDE5, VASP, and p44/42 as determined by densitometric analysis of the ratios of p-PDE5 to GAPDH, p-VASP to VASP, and p44/42 to
GAPDH, respectively. Values were normalized to the respective control conditions (1 nMCNP or 10 nMCNP in the absence of SIL). Representative data from one
of three independent experiments are shown.
(C) B16 cells were grown for 48 hr under control conditions or in the presence of 1 mMCNP or 1 mMCNP plus 100 mMsildenafil. Then, cell growth was determined
by the MTS assay. Data were normalized to growth under control conditions, which was set to 1, and presented as mean ± SEM (n = 4); *p < 0.05 compared to
control.
(D) B16 cell growth was continuously monitored by impedance-based RTCA. Cells were grown under control conditions or in the presence of 1 mMCNP or 1 mM
CNP plus 100 mM sildenafil. Data are shown as mean ± SEM (n = 3); ***p < 0.001 compared to control.
(E and F) B16 melanoma cells were injected intracutaneously (i.c.) into C57BL/6 mice (23 75,000 cells/mouse). A subgroup of the experimental animals received
sildenafil (200 mg kg1day1) in their drinking water, while the remaining mice had water without the drug. Administration of sildenafil was started 2 days before
injection of the melanoma cells and continued throughout the study. (E) At the end of the study (day 13 after injection of melanoma cells), the cGMP levels in the
hearts of control and sildenafil-treated mice were determined by enzyme immunoassay. Data are presented as mean values (n = 2 mice per group). (F) Tumor
growth curves were determined by measuring the tumor volume over time. Data are shown as mean ± SEM (n = 20 tumors from control mice and n = 18 tumors
from sildenafil-treated mice). Differences between groups were assessed by repeated-measures ANOVA followed by a Bonferroni t test; *p < 0.05.cytosolic Ca2+ and promoted the invasiveness of the melanoma
cells. However, the effect of sildenafil on the growth of primary
tumors was not determined in this study, and the potential
cGMP generators and effectors were not identified. Thus, while
Arozarena et al. describe an influence of MAPK on cGMP
signaling, in that enhanced MAPK activity results in increased
cGMP levels via downregulation of PDE5, our study reportsCellvice versa that cGMP also impacts MAPK signaling, in that
increased levels of cGMP enhance the activity of MAPK via
cGKI. Arozarena and colleagues could not detect cGKI expres-
sion in seven BRAF mutant melanoma cell lines analyzed in their
study (Arozarena et al., 2011). Our expression analysis of a panel
of humanmelanoma cell lines and tumor sections of human mel-
anoma patients also indicated that cGKI is probably not the onlyReports 14, 2599–2610, March 22, 2016 ª2016 The Authors 2605
Figure 7. Human Melanoma Cells Also Express a Growth-Promoting cGMP Pathway
(A) Analysis of cGKIa and cGKIbmRNA expression in human melanoma cell lines by qRT-PCR. Data normalization was carried out against 18S rRNA, and values
were referenced to the mean expression level of non-metastatic, radial growth phase (RGP) melanoma cell lines (WM35, WM1552, WM3211, SBCL2). Primary
and metastatic melanoma cell lines are indicated by the horizontal brackets. The mutation status of BRAF and NRAS for each cell line is given below the diagram
(open squares and filled squares denote wild-type and mutated, respectively). More information about the cell lines is given in Table S1. Data were analyzed in
triplicates and are presented as mean ± SD (n = 3).
(B) Immunohistochemical detection of cGKI (brown) in humanmelanoma sections. Representative photomicrographs of a cGKI-positive primary tumor (left panel)
and a cGKI-negative metastasis (right panel) of the same patient; scale bars, 100 mm. The insets show overviews of the respective sections; scale bars, 250 mm.
Note that the well-known expression of cGKI in blood vessels is also detected, which serves as a positive control for successful immunostaining of the sections.
(C) cGMP levels in WM3211 (black bars) and 1205Lu (gray bars) humanmelanoma cells. Cells were incubated for 10 min in PBS or in PBS with 1 mMCNP or 1 mM
CNP plus 100 mM sildenafil (SIL). Then, cells were lysed, and cGMP levels were determined in cell extracts by an enzyme immunoassay. Data are presented as
mean ± SEM (n = 3); ***p < 0.001 compared to PBS.
(D) WM3211 or 1205Lu human melanoma cells were incubated for 10 min under control condition (PBS) or in the presence of 100 mM 8-Br-cGMP (cG) or 1 mM
CNP. Then, cell lysates (10 mg) were analyzed by western blot with the indicated antibodies. GAPDH was used as a loading control. Values below the panels
represent fold increase in p44/42 phosphorylation as determined by densitometric analysis of the p-p44/42 to GAPDH ratio and normalization to control con-
ditions (cells incubated with PBS). Representative data from one of two independent experiments are shown.
(E) WM3211 (black bars) and 1205Lu (gray bars) cells were grown for 48 hr under control conditions or in the presence of 1 mM 8-Br-cGMP, 1 mMCNP, or 1 mM
CNP plus 100 mM sildenafil (SIL). Then, cell growth was determined by the MTS assay. Data were normalized to growth under control conditions, which was set
to 1, and presented as mean ± SEM (n = 4); *p < 0.05 and **p < 0.01 compared to control.
See also Figures S2, S3, S4, and S5.effector of cGMP in melanoma cells. Taken together, the results
from the present study and from Arozarena et al. (2011) may
reflect the well-known heterogeneity of melanoma cells and sug-2606 Cell Reports 14, 2599–2610, March 22, 2016 ª2016 The Authorgest that the functional outcome of increased cGMP in mela-
noma cells may in fact depend on the availability of cGKI or alter-
native cGMP effectors, which have yet to be identified. Indeed,s
the survival of melanoma patients correlates with the expression
level of cGKI in their tumors, with a dramatically shorter median
survival time for patients with high cGKI expression (Figure S3).
Based on the present study and previous findings (Arozarena
et al., 2011; Scho¨nrath et al., 2011), we suggest a model in which
a bidirectional crosstalk of cGMP and MAPK signaling promotes
the switch of non-metastatic cells in primary melanomas to inva-
sive/metastatic cells. In this model (Figure S5), CNP via GC-B
stimulates cGMP generation in melanoma cells of primary tu-
mors resulting in activation of cGKIa and p44/42MAPK, resulting
in cells with increased potential for growth, migration, and inva-
siveness to develop. Degradation of cGMP via PDE5 acts as a
brake in this switching process. However, a persistent increase
in MAPK signaling, for instance, by sustained activity of the
cGMP-cGKI cascade and/or by somatic gain-of-function muta-
tion of BRAF, results in downregulation of PDE5. This releases
the PDE5 brake, thus establishing a feedforward, self-reinforcing
loop that further enhances the aggressiveness of the melanoma
cells. Importantly, the PDE5 brake can also be released pharma-
cologically by sildenafil, thus explaining the pro-melanoma ef-
fects of this drug (Figure S5). Since primary melanomas appear
to express substantially higher levels of cGKI (Figure 7B; data
not shown) and PDE5 (Arozarena et al., 2011) than metastases,
it is likely that CNP and sildenafil act primarily on cells of primary
tumors and promote their metastatic potential. Cancer metas-
tasis requires multiple steps including resistance to anoikis,
which is defined as induction of apoptosis due to detachment
from the extracellular matrix (Buchheit et al., 2014). Indeed, we
have shown previously that in vascular smooth muscle cells acti-
vation of cGKI promotes cell adhesion and survival (Weinmeister
et al., 2008; Wolfsgruber et al., 2003) leading us to propose that
cGMP-cGKI signaling can protect cells from anoikis (Weinmeis-
ter et al., 2008). A similar mechanism may contribute to cGMP-
mediated growth of melanoma cells and tumor progression.
Finally, it is important to note that cGMP generation inmelanoma
cells is initially triggered by CNP and that a basal CNP tonus
would also be required for an increase in cGMP after PDE5
downregulation/inhibition. It is well known that CNP can be
secreted by endothelial cells, particularly in the presence of cy-
tokines (Potter et al., 2006). Thus, it is likely that the pro-melano-
magenic CNP is released by the tumor vasculature, particularly
under inflammatory conditions, also providing a link between
inflammation and melanoma (Figure S5).
Our data together with the findings of Arozarena et al. (2011)
raise concerns that the use of sildenafil (Viagra) or other PDE5 in-
hibitors like vardenafil (Levitra) or tadalafil (Cialis) could promote
melanoma in humans. These drugs are the first-line therapy for
most men with erectile dysfunction. Indeed, a recent long-term
cohort study that included 14,912 men in the United States indi-
cated that men who used sildenafil for erectile dysfunction had a
significantly elevated risk of melanoma (Li et al., 2014). The link
between sildenafil and melanoma development is further sup-
ported by the finding that PDE5 inhibitors promote melanin syn-
thesis (Zhang et al., 2012), which may exacerbate melanoma
development (Noonan et al., 2012). PDE5 inhibitors are also
used for the treatment of benign prostate hyperplasia and pul-
monary arterial hypertension, and there is a tremendous growth
of preclinical and clinical studies exploring new applications ofCellPDE5 inhibitors, such as the management of cardiovascular dis-
eases, diabetes, and even cancer (Das et al., 2015; Ghofrani
et al., 2006; Shi et al., 2011). In principle, pharmacological mod-
ulation of cGMP signaling can affect both the tumor cells and the
tumormicroenvironment. For example, sildenafil was reported to
have anti-inflammatory effects and to augment endogenous
antitumor immunity in several mouse tumor models (Serafini
et al., 2006) including melanoma (Meyer et al., 2011). There are
also studies indicating that PDE5 inhibition can directly induce
apoptosis and growth inhibition of tumor cells in vitro (Sarfati
et al., 2003; Tinsley et al., 2009; Zhu et al., 2005). A recent report
suggested that activation of the 67-kDa laminin receptor on can-
cer cells by a green tea polyphenol increases cGMP and induces
cancer-selective apoptosis (Kumazoe et al., 2013). In a mouse
breast cancer model, PDE5 inhibition by vardenafil potentiated
the anticancer effect of the green tea polyphenol. Interestingly,
however, when vardenafil was given alone, tumor growth ap-
peared to increase compared to control animals that did not
receive drugs (Kumazoe et al., 2013). Thus, the effects of
cGMP signaling and its pharmacological stimulation by PDE5
inhibitors on tumorigenesis are complex and might depend on
tumor type and context. Although it is not clear whether the sil-
denafil concentration used in our experiments is also reached
in patients, the results of the preclinical melanoma models ob-
tained in the present study and elsewhere (Arozarena et al.,
2011; Noonan et al., 2012; Zhang et al., 2012) combined with
the recent finding of increased melanoma risk in men using sil-
denafil (Li et al., 2014) suggest that possible skin adverse effects
of PDE5 inhibitors should be considered at least in patients with
melanoma.
Taken together, this study has uncovered a previously un-
known cGMP-cGKI signaling cascade inmurine and humanmel-
anoma cells. Activation of this pathway promotes tumor cell
growth in vitro and in vivo. This pathway also provides a mecha-
nism for the reported pro-melanoma effects of sildenafil and it
could be an interesting therapeutic target in melanoma. Our find-
ings in melanoma cells also support the general notion that
signaling via cGMP and cGKI promotes phenotypic modulation,
growth, and survival of various cell types when they are exposed
to inflammation and/or stress, such as vascular smooth muscle
cells (Wolfsgruber et al., 2003), bone marrow progenitor cells
(Aicher et al., 2009), cardiomyocytes (Fiedler et al., 2006), eryth-
rocytes (Fo¨ller et al., 2008), cochlear hair cells (Jaumann et al.,
2012), and bone cells (Marathe et al., 2012).
EXPERIMENTAL PROCEDURES
For detailed procedures and reagents, see Supplemental Experimental
Procedures.
Analysis of Gene Expression, Signaling Pathways, Cell Growth, and
Cell Migration
Murine B16 melanoma cells were grown in DMEM (Life Technologies) and
human melanoma cells were grown in RPMI 1640medium (Life Technologies).
Media were supplemented with 10% fetal calf serum, 100 U/ml penicillin, and
100 mg/ml streptomycin. Cells were grown at 37C and 6% CO2 in a humidi-
fied incubator. Further information on the human melanoma cell lines is pro-
vided in Table S1.
For RT-PCR analysis, total RNA was isolated from serum-starved (3 hr) cells
or from mouse tissues, reverse transcribed, and then amplified using theReports 14, 2599–2610, March 22, 2016 ª2016 The Authors 2607
primer pairs indicated in Supplemental Experimental Procedures and Table
S2. For western blot analysis, serum-starved (3 hr) cells were treated for
10 min with test substances in PBS at 37C in a 6%CO2 incubator. Then, cells
were lysed in SDS-containing lysis buffer, and protein lysates were subjected
to western blot analysis as described (M€uller et al., 2012). Primary antibodies
are listed in Supplemental Experimental Procedures. For immunofluorescence
staining, formalin-fixed cells were incubated with cGKI antibody (1:1,000)
(Valtcheva et al., 2009) for 1 hr. For immunohistochemical staining of human
tissue sections, paraffin sections were incubated with cGKI antibody (1:500)
(Valtcheva et al., 2009) for 12 hr. Archived tissue samples of melanomas be-
tween the years 2001 and 2006 from patients of the Department of Derma-
tology, Inselspital, Bern, Switzerland, were included in this study. The study
was approved by the Internal Review Board of the Inselspital.
To measure the levels of cGMP and cAMP, cells were grown in 6-well plates
and serum starved for 3 hr. Then, they were incubated with various drugs at
37C. For cGMP/cAMP immunoassays (Cyclic GMP EIA Kit, Cyclic AMP EIA
Kit; Cayman Chemical), cells or tissues were extracted with ice-cold ethanol,
and cyclic nucleotide levels were determined as described (M€uller et al.,
2012). Alternatively, intracellular cGMP signals were monitored in living
cells that had been transfectedwith a plasmid encoding the fluorescence reso-
nance energy transfer (FRET)-based cGMP sensor, cGi500 (Russwurm et al.,
2007). FRET/cGMP imaging of the cells was performed 48 hr after transfection
as described previously (Thunemann et al., 2013a, 2013b).
To determine cell growth, cells that had been serum starved for 18 hr were
grown in the absence or presence of drugs in medium containing 10% FCS.
Cell growth was analyzed by an MTS assay (CellTiter 96 AQueous Non-Radio-
active Cell Proliferation Assay, Promega) or, alternatively, by using an
xCELLigence Real Time Cell Analyzer Dual Plate (RTCA DP, Roche) with 16-
well plates (E-plate, Roche). The RTCA uses a unitless parameter termed cell
index (CI) to measure relative changes in electrical impedance and cell status.
To monitor cell migration, cells were serum starved for 18 hr. Then, a scratch
assaywas performed using m-DishCulture-Inserts (35mm, high, Ibidi). Alterna-
tively, cell migration through a membrane with 8 mm-pores was monitored in
real time by using the RTCA with modified 16-well plates (CIM-16, Roche).
In Vivo Tumor Growth Model
B16F10 melanoma cells were exposed to adenovirus (MOI = 100) encoding
EGFP (Ad-EGFP) or EGFP and bovine cGKIa (Ad-cGKIa) in serum-free me-
dium for 15 min followed by the addition of medium containing 10% FCS for
48 hr. Then, cells were injected intracutaneously (i.c.) into the dorsal skin of
anesthetized 5- to 6-week-old female C57BL/6 mice (23 75,000 cells per
mouse). For PDE5 inhibition, sildenafil citrate (Molekula, kindly provided by
R. Lukowski, T€ubingen) was given orally in the drinking water to a subgroup
of mice (200 mg kg–1day–1). Administration of sildenafil started 2 days before
injection of B16 melanoma cells and was continued for the whole course of
the experiment. Tumor size was measured by caliper every 2–3 days, and,
on day 13 or 14, animals were sacrificed and tumors were removed by surgery.
All animal experiments were approved by the local authority (Regierungspra¨si-
dium T€ubingen, HT11/13).
Statistics
Data are expressed asmean ±SEM, if not otherwise stated. Independent sam-
ples were compared with unpaired Student’s t test and differences between
groups of mice were analyzed by repeated-measures ANOVA followed by a
Bonferroni t test. p values <0.05 were considered to be significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.028.
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